论文部分内容阅读
最近英国报道了应用HMG-CoA还原酶抑制ML-236B治疗家族性高胆固醇血症。经临床观察对杂合子家族性高胆固醇具有明显疗效,并且血清CoQ_(s10)水平保持正常水平。 HMG-CoA还原酶是胆固醇生物合成过程中限速酶,ML-236B是该酶的竞争性抑制剂,用ML-236B可抑制胆固醇的合成,从而降低血清胆固醇。临床观察ML-236B所用剂量30～60mg/日,持续24周,血清胆固醇由390±9mg降到303±9mg/分升,
Recently, the UK reported the use of HMG-CoA reductase to inhibit ML-236B in the treatment of familial hypercholesterolemia. The clinical observation of heterozygous familial high cholesterol has a significant effect, and maintain normal serum CoQ_ (s10) levels. HMG-CoA reductase is the rate-limiting enzyme in the process of cholesterol biosynthesis. ML-236B is a competitive inhibitor of this enzyme. ML-236B inhibits the synthesis of cholesterol and thus reduces serum cholesterol. Clinical observation ML-236B dose 30 ~ 60mg / day for 24 weeks, serum cholesterol decreased from 390 ± 9mg 303 ± 9mg / dl,